Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2005-11-22
2005-11-22
Johannsen, Diana B. (Department: 1634)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C435S006120, C435S091200, C435S091510
Reexamination Certificate
active
06967016
ABSTRACT:
The invention relates to the diagnosis of disease or the determination of functioning of cellular organisms, being of multi-cellular or unicellular nature, being visible by the naked eye or being a microorganism. The invention provides a method for determining functioning of a cellular organism comprising determining the relative ratio of a first endosymbiont cellular organelle nucleic acid and/or gene product thereof in a sample obtained from the organism in relation to the amount of a second nucleic acid and/or gene product thereof.
REFERENCES:
patent: 5569754 (1996-10-01), Williams et al.
patent: 6221600 (2001-04-01), MacLeod et al.
patent: 6232065 (2001-05-01), Robinson et al.
patent: 2002/0048763 (2002-04-01), Penn et al.
patent: 2002/0049176 (2002-04-01), Anderson et al.
patent: 2002/0169562 (2002-11-01), Stephanopoulos et al.
patent: 2003/0003488 (2003-01-01), Ramakrishnan
patent: 2003/0099933 (2003-05-01), Cote et al.
patent: WO 96/06191 (1996-02-01), None
patent: WO 97/39149 (1997-10-01), None
patent: WO 98/17826 (1998-04-01), None
patent: WO 99/66075 (1999-12-01), None
de Muys, J.-M. et al. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2′-deoxy-3′-oxa-4′-thiocytidine. Antimicrobial Agents and Chemotherapy 43(8):1835-1844 (Aug. 1999).
Brinkman, K. et al. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Current Opinion in Infectious Diseases 13(1):5-11 (Feb. 2000).
Moyle, G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clinical Therapeutics 22(8):911-936 (Aug. 2000).
Williams R.S., Mitochondrial Gene Expression in Mammalian Striated Muscle. Evidence That Variation in Gene Dosage is the Major Regulatory Event, J. Biol. Chem., 261(26) :12390-12394 (1986).
Williams et al., Regulation of Nuclear and Mitochondrial Gene Expression by Contractile Activity in Skeletal Muscle,□□J. Biol. Chem., 261(1) : 376-380 (1986).
Voehringer et al., Gene microarray identification of redox and mitochondrial elements that control resistance or sensitivity to apoptosis. PNAS 97(6):2680-5 (Mar. 2000).
DeRisi et al., Exploring the metabolic and genetic control of gene expression on a genomic scale.Science. 278(5338) : 680-6 (Oct. 1997).
DeRisi et al., Use of a cDNA microarrays to analyze gene expression patterns in human cancer. Nature Genetics 14(4) : 457-460 (Dec. 1996).
Schena M., Genome analysis with gene expression microarrays. BioEssays 18(5) : 427-431 (1996).
Schena et al., Parallel human genome analysis: microarray-based expression monitoring of1000 genes. PNAS 93 (20) : 10614-9 (Oct. 1996).
Schena et al., Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270 (5235) : 467-70 (1995).
Lockhart et al., Expression monitoring by hybridization to high-density oligonucleotide arrays. Nature Biotechnology 14 (13) : 1675-80 (Dec. 1996).
Partial European Search Report, EP 00 20 4322, dated Oct. 31, 2001.
Abbott, A.G., et al., “Quantitative variation in components of the maize mitochondrial genome between tissues and between plants with different male-sterile cytoplasms,” 4 Plant Molecular Biology 233-240 (1985).
Anderson, C.M., et al., “Mitochondrial Electron Transport Complexes are Decreased in Skeletal Muscle in Type II Diabetes Mellitus,” Abstracts from the 59th Session, p. a259 (Jun. 1999).
Boultwood, J., et al., “Amplification of mitochondrial DNA in acute myeloid leukaemia,” 95 British Journal of Haematology 426-431 (1996).
Lee, H.K., et al., “Decreased mitochondiral DNA content in peripheral blood precedes the development of non-insulin-dependent diabetes mellitus,” 42 Diabetes Research and Clinical Practice 161-167 (1998).
Su, C., et al., “Selective reduction of creatine kinase subunit mRNAs in striated muscle of diabetic rats,” 263 American Journal of Physiology e310-e316 (1992).
Tepper, C.G., “Resistance of Mitochondrial DNA to Degradation Characterizes the Apoptotic but Not the Necrotic Mode of Human Leukemia Cell Death,” 52 Journal of Cellular Biochemistry 352-361 (1993).
Partial European Search Report, International Application No. EP 00 20 4322, dated Oct. 31, 2001 (3 pages).
de Ronde Anthonij
Dobbelaer Irene Johanna M.
Gemen Bob van
Timmermans Eveline Catherina A. C.
Johannsen Diana B.
PrimaGen Holding B.V.
TraskBritt
LandOfFree
Method of determining therapeutic activity and/or possible... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of determining therapeutic activity and/or possible..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of determining therapeutic activity and/or possible... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3491129